CN100586453C - 一种颈复康片的制备方法 - Google Patents
一种颈复康片的制备方法 Download PDFInfo
- Publication number
- CN100586453C CN100586453C CN200610080714A CN200610080714A CN100586453C CN 100586453 C CN100586453 C CN 100586453C CN 200610080714 A CN200610080714 A CN 200610080714A CN 200610080714 A CN200610080714 A CN 200610080714A CN 100586453 C CN100586453 C CN 100586453C
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- rhizoma
- volatile oil
- processed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims description 17
- 239000003814 drug Substances 0.000 claims abstract description 18
- 239000000341 volatile oil Substances 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- 239000000843 powder Substances 0.000 claims description 40
- 238000001035 drying Methods 0.000 claims description 30
- 210000000582 semen Anatomy 0.000 claims description 28
- 239000003921 oil Substances 0.000 claims description 25
- 241000717739 Boswellia sacra Species 0.000 claims description 24
- 239000004863 Frankincense Substances 0.000 claims description 24
- 241001057584 Myrrha Species 0.000 claims description 24
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 239000007864 aqueous solution Substances 0.000 claims description 21
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 17
- 241000756943 Codonopsis Species 0.000 claims description 16
- 238000000576 coating method Methods 0.000 claims description 15
- 241000903946 Clematidis Species 0.000 claims description 14
- 241001489978 Eupolyphaga Species 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 14
- 241000237636 Pheretima Species 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 14
- 241000545442 Radix Species 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 13
- 235000019640 taste Nutrition 0.000 claims description 13
- 229920000858 Cyclodextrin Polymers 0.000 claims description 11
- 239000001116 FEMA 4028 Substances 0.000 claims description 11
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 11
- 229960004853 betadex Drugs 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 238000004321 preservation Methods 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 8
- 241000219780 Pueraria Species 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 8
- 208000002193 Pain Diseases 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 3
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 239000008187 granular material Substances 0.000 description 12
- 239000009636 Huang Qi Substances 0.000 description 11
- 239000008280 blood Substances 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 238000005242 forging Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 7
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 6
- 208000036319 cervical spondylosis Diseases 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 208000005801 spondylosis Diseases 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 239000012567 medical material Substances 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 229950005770 hyprolose Drugs 0.000 description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 4
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 208000004044 Hypesthesia Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000034783 hypoesthesia Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001676635 Lepidorhombus whiffiagonis Species 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041415 Spastic paralysis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000029761 vertebral disease Diseases 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610080714A CN100586453C (zh) | 2006-05-12 | 2006-05-12 | 一种颈复康片的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610080714A CN100586453C (zh) | 2006-05-12 | 2006-05-12 | 一种颈复康片的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1872229A CN1872229A (zh) | 2006-12-06 |
CN100586453C true CN100586453C (zh) | 2010-02-03 |
Family
ID=37482938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200610080714A Active CN100586453C (zh) | 2006-05-12 | 2006-05-12 | 一种颈复康片的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100586453C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101979011A (zh) * | 2010-10-29 | 2011-02-23 | 上海蓝怡科技有限公司 | 治疗颈椎病的中药经皮凝胶膏剂及其制备方法 |
-
2006
- 2006-05-12 CN CN200610080714A patent/CN100586453C/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN1872229A (zh) | 2006-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104367879A (zh) | 一种用于治疗鸡劳伤的药物组合物及其制备方法 | |
CN102895501A (zh) | 一种治疗不寐的药物 | |
CN101011483B (zh) | 治疗小儿消化系统疾病的中药制剂及其制备方法 | |
CN103536838B (zh) | 一种治疗先兆流产的中药制剂及其制备方法 | |
CN102671178B (zh) | 一种治疗肾病综合症及尿毒症的中药组合物配制方法及应用 | |
CN107095905A (zh) | 一种保健灸条及灸膏 | |
CN102028927B (zh) | 一种治疗急慢性支气管炎的外敷贴膏及其制备方法 | |
CN102847061A (zh) | 一种治疗小儿病毒性心肌炎的中药制剂及其制备方法 | |
CN103191331B (zh) | 用于治疗支气管哮喘缓解期的中药组合物 | |
CN102895610A (zh) | 一种治疗水肿的药物 | |
CN100586453C (zh) | 一种颈复康片的制备方法 | |
CN106377700A (zh) | 一种桑叶苦瓜茶及其制备方法 | |
CN106177392A (zh) | 一种治疗外感高热的汤剂药物及其制备方法 | |
CN102293941B (zh) | 一种治疗糖尿病的中药组合物 | |
CN104998158A (zh) | 一种治疗肝硬化的药物组合物及其应用 | |
CN106309870A (zh) | 一种具有安神助眠作用的中药组合物 | |
CN101284059A (zh) | 一种补脾肾,治疗慢性肾炎的中药制剂及其制备方法 | |
CN104940766A (zh) | 一种调理亚健康的铁皮石斛中药组合物 | |
CN101028425A (zh) | 治疗痤疮的药物 | |
CN103990018A (zh) | 一种抗糖尿病的中药制剂 | |
CN103202941A (zh) | 滋补强身药酒 | |
CN102552824B (zh) | 用于治疗银屑病的中成药 | |
CN101085312A (zh) | 一种治疗甲亢的中药 | |
CN105288143A (zh) | 一种治疗哮喘的中药组合物 | |
CN105663785A (zh) | 一种用于治疗偏头痛的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Effective date: 20110830 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20110830 Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 4002 Patentee after: Beijing Increase Pharmaceutical Technology Co., Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: Beijing Yinkeruisi Biological Products Research Institute |
|
ASS | Succession or assignment of patent right |
Owner name: ZHUHAI BAODE RUNSHENG HEALTH TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20150320 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100088 XICHENG, BEIJING TO: 519040 ZHUHAI, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150320 Address after: 519040 Guangdong city of Zhuhai province Jinwan District Sanzao Town Airport Road No. 288 building four floor F area B Patentee after: Zhuhai Bao Derun Health Technology Co., Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 4002 Patentee before: Beijing Increase Pharmaceutical Technology Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20161223 Address after: Beijing city Changping District town Beiqijia Hongfu building room 1009 Patentee after: BEIJING INCREASE PHARMACEUTICAL INSTITUTE CO., LTD. Address before: 519040 Guangdong city of Zhuhai province Jinwan District Sanzao Town Airport Road No. 288 building four floor F area B Patentee before: Zhuhai Bao Derun Health Technology Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170629 Address after: Room 20, 408, creative Valley, 1889 Huandao East Road, Hengqin New District, Xiangzhou, Guangdong, Zhuhai Patentee after: Ying Kerui (Hengqin) Pharmaceutical Research Institute Co Ltd Address before: Beijing city Changping District town Beiqijia Hongfu building room 1009 Patentee before: BEIJING INCREASE PHARMACEUTICAL INSTITUTE CO., LTD. |
|
TR01 | Transfer of patent right |